SilverCloud Health vs Regeneron Pharmaceuticals
Side-by-side comparison of AI visibility scores, market position, and capabilities
Digital mental health platform delivering evidence-based CBT programs, Dublin Ireland, acquired by Amwell, serves 500+ health systems and payers globally.
About
SilverCloud Health is a Dublin, Ireland-based digital mental health platform founded in 2012 at Trinity College Dublin. The company specializes in delivering structured, evidence-based cognitive behavioral therapy (CBT) programs through an asynchronous digital format supported by a trained human reviewer. SilverCloud was acquired by Amwell in 2021, integrating its digital mental health programs into Amwell's broader virtual care platform serving health systems, health plans, and employers.\n\nThe platform offers more than 20 condition-specific programs covering depression, anxiety, insomnia, chronic pain, diabetes, and workplace stress, among others. Each program is built on clinically validated CBT frameworks and follows a structured curriculum over six to eight weeks. Users work through modules independently and receive feedback and encouragement from a trained human supporter, a model known as supported self-management that has shown strong outcomes in peer-reviewed research.\n\nSilverCloud serves more than 500 health systems, insurers, and employers across the United Kingdom, Ireland, and the United States. Its clinical credibility is underpinned by a robust evidence base of over 90 published research studies, making it one of the most rigorously evaluated digital mental health interventions available. Following the Amwell acquisition, SilverCloud has expanded its reach through Amwell's existing hospital and health plan relationships.
Regeneron (REGN) reported $13.9B revenue in FY2024, up 7% YoY. Top biotech company. Dupixent franchise >$14B. Leaders in eye disease, immunology, oncology. HQ: Tarrytown, NY.
About
Regeneron Pharmaceuticals, Inc. is a leading biotechnology company specializing in the discovery, development, and commercialization of medicines for serious diseases, headquartered in Tarrytown, New York. Founded in 1988 by Leonard Schleifer and George Yancopoulos, Regeneron developed its own proprietary drug discovery technology platform (VelociGene, VelocImmune) that has enabled the development of multiple breakthrough medicines. The company reported revenues of $13.9B in FY2024, up 7% year-over-year.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Integrations
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.